Additionally, chemotherapy with H (OR, 4.164; 95% CI, 2.457‐7.058; P < .001), chemotherapy with HP (OR, 3.172; 95% CI, 1.788‐5.628; P < .001), clinical N1 stage at diagnosis (OR, 1.755; 95% CI, 1.089‐2.826; P = .021) and ER negativity (OR, 1.652; 95% CI, 1.080‐2.526; P = .021) were significant predictors for axillary pCR after adjusting age and tumor size (Table 2). This evidence concerns the gene ESR1 and neoplasm.